E1	Procedure:T1 Name:T2 Temporality:E30 Minimum-Count:E31
E3	Procedure:T3 Name:T4
E5	Procedure:T5 Name:T6
E7	Condition:T7 Name:T8 Severity:T78 Temporality:E16
E9	Condition:T9 Name:T10 Severity:T76
E11	Condition:T11 Name:T12
E13	Condition:T13 Name:T14
E15	Procedure:T15 Name:T16
E16	Eq-Comparison:T28 Operator:T17 Temporal-Unit:T20 Value:T26
E17	Eq-Comparison:T29 Operator:T18 Value:T27 Unit:T90
E18	Eq-Comparison:T30 Operator:T21 Value:T24 Value2:T25
E21	Eq-Comparison:T33 Temporal-Period:T34
E22	Eq-Comparison:T35 Temporal-Period:T36
E2	Condition:T31 Name:T32
E4	Modifier:T41 Modifies:T32
E6	Modifier:T42 Modifies:T32
E8	Modifier:T43 Modifies:T32
E10	Modifier:T44 Modifies:T32
E12	Or:T45 Arg:E10 Arg2:E8
E14	Eq-Comparison:T46 Operator:T47 Value:T22 Value2:T23 Temporal-Unit:T19
E19	Age:T48 Eq-Comparison:E14
E20	Condition:T49 Name:T50
E25	Or:T52 Arg:T51 Arg2:E26
E26	Condition:T53 Name:T54
E23	Condition:T37 Name:T38
E27	Modifier:T56 Modifies:T38
E28	Modifier:T57 Modifies:T38
E29	Or:T58 Arg:E28 Arg2:E27
E30	Eq-Comparison:T59 Temporal-Period:T60
E31	Eq-Comparison:T61 Value:T62
E32	And:T63 Arg:E1 Arg2:E5
E33	Condition:T64 Name:T65
E34	Condition:T66 Name:T67 Stage:E18
E24	Procedure:T39 Temporality:E22
E35	Drug:T40 Name:T68
E36	Drug:T69 Name:T70
E37	Drug:T71 Name:T72
E38	Or:T73 Arg:E36 Arg2:E37
E39	Modifier:T74 Modifies:T10
E40	Modifier:T75 Modifies:T10
E41	Or:T77 Arg:E40 Arg2:E39
E42	Study:T79
E43	Temporal-Connection:T80 Arg:E16 Arg2:E42
E44	Condition:T81 Name:T82 Severity:T83
E45	Modifier:T84 Modifies:T82
E46	Or:T85 Arg:E45 Arg2:T83
E47	Condition:T86 Name:T87
E48	Condition:T88 Name:T89 Stage:E17
E49	Or:T91 Arg:E48 Arg2:E13
E50	Assertion:T92 Asserted:E15
T1	Procedure 301 313	chemotherapy
T2	Procedure-Name 301 313	chemotherapy
T3	Procedure 257 274	endocrine therapy
T4	Procedure-Name 257 274	endocrine therapy
T5	Procedure 372 389	endocrine therapy
T6	Procedure-Name 372 389	endocrine therapy
T7	Condition 666 693	acute myocardial infarction
T8	Condition-Name 666 693	acute myocardial infarction
T9	Condition 621 629	diseases
T10	Condition-Name 621 629	diseases
T11	Condition 756 780	Congestive heart failure
T12	Condition-Name 756 780	Congestive heart failure
T13	Condition 831 853	ventricular arrhythmia
T14	Condition-Name 831 853	ventricular arrhythmia
T15	Procedure 873 885	intervention
T16	Procedure-Name 873 885	intervention
T17	Eq-Operator 694 700	within
T18	Eq-Operator 822 823	>
T19	Eq-Temporal-Unit 178 183	years
T20	Eq-Temporal-Unit 703 709	months
T21	Eq-Operator 439 440	-
T22	Eq-Value 170 172	18
T23	Eq-Value 175 177	75
T24	Eq-Value 438 439	0
T25	Eq-Value 440 441	1
T26	Eq-Value 701 702	6
T27	Eq-Value 824 825	2
T28	Eq-Comparison 694 709	within 6 months
T29	Eq-Comparison 816 825	class > 2
T30	Eq-Comparison 438 440	0-
T33	Eq-Comparison 242 256	Received prior
T34	Eq-Temporal-Period 242 256	Received prior
T35	Eq-Comparison 480 494	received prior
T36	Eq-Temporal-Period 480 494	received prior
T31	Condition 152 158	Cancer
T32	Condition-Name 152 158	Cancer
T41	Modifier 131 151	HER2 negative Breast
T42	Modifier 104 129	hormone-receptor positive
T43	Modifier 92 102	metastatic
T44	Modifier 71 88	locally recurrent
T45	Or 89 91	or
T46	Eq-Comparison 170 183	18 - 75 years
T47	Eq-Operator 173 174	-
T48	Age 165 168	Age
T49	Condition 189 203	postmenopausal
T50	Condition-Name 189 203	postmenopausal
T51	Life-Stage-And-Gender 204 209	women
T52	Or 210 212	or
T53	Condition 213 230	prepostmenopausal
T54	Condition-Name 213 230	prepostmenopausal
T55	Life-Stage-And-Gender 231 236	women
T37	Condition 338 345	disease
T38	Condition-Name 338 345	disease
T56	Modifier 327 337	metastatic
T57	Modifier 318 326	advanced
T58	Or 326 327	/
T59	Eq-Comparison 284 292	previous
T60	Eq-Temporal-Period 284 292	previous
T61	Eq-Comparison 280 283	One
T62	Eq-Value 280 283	One
T63	And 357 368	in addition
T64	Condition 396 430	Eastern Cooperative Oncology Group
T65	Condition-Name 396 430	Eastern Cooperative Oncology Group
T66	Condition 432 436	ECOG
T67	Condition-Name 432 436	ECOG
T39	Procedure 495 504	treatment
T40	Drug 514 530	CDK4/6 inhibitor
T68	Drug-Name 514 530	CDK4/6 inhibitor
T69	Drug 532 542	everolimus
T70	Drug-Name 532 542	everolimus
T71	Drug 546 556	fulvestant
T72	Drug-Name 546 556	fulvestant
T73	Or 543 545	or
T74	Modifier 605 620	cerebrovascular
T75	Modifier 586 600	cardiovascular
T76	Severity 574 585	significant
T77	Or 601 604	and
T78	Severity 659 665	severe
T79	Study 717 727	enrollment
T80	Temporal-Connection 710 716	before
T81	Condition 748 754	angina
T82	Condition-Name 748 754	angina
T83	Severity 741 747	severe
T84	Modifier 729 737	unstable
T85	Or 738 740	or
T86	Condition 782 808	New York heart association
T87	Condition-Name 782 808	New York heart association
T88	Condition 810 814	NYHA
T89	Condition-Name 810 814	NYHA
T90	Eq-Unit 816 821	class
T91	Or 828 830	or
T92	Assertion 860 864	need
A1	Eq-Operator-Value T17 LTEQ
A2	Eq-Operator-Value T18 GT
A3	Eq-Temporal-Unit-Value T19 year
A4	Eq-Temporal-Unit-Value T20 month
A5	Eq-Operator-Value T21 BETWEEN
A8	Eq-Temporal-Period-Value T34 past
A9	Eq-Temporal-Period-Value T36 past
A6	Eq-Operator-Value T47 BETWEEN
A7	Life-Stage-And-Gender-Type T51 female
A12	Life-Stage-And-Gender-Type T55 female
A10	Eq-Temporal-Period-Value T60 past
A11	Severity-Value T76 severe
A13	Severity-Value T78 severe
A14	Temporal-Connection-Type-Value E43 before
A15	Severity-Value T83 severe
A16	Assertion-Type-Value E50 hypothetical
R1	If-Then Arg1:T51 Arg2:E20
R2	If-Then Arg1:T55 Arg2:E26
R3	Treatment-For Arg1:E1 Arg2:E23
R4	Abbrev-Of Arg1:E34 Arg2:E33
R5	Using Arg1:E24 Arg2:E35
R6	Example-Of Arg1:E7 Arg2:E9
R7	Equivalent-To Arg1:E47 Arg2:E11
R8	Abbrev-Of Arg1:E48 Arg2:E47
R9	Treatment-For Arg1:E15 Arg2:E13